Complications in Process Simulation Execution
Regulators have exaggerated expectations for simulated media fills.
Regulators have exaggerated expectations for simulated media fills.
This article reviews aspects of media fill execution in which regulatory expectations have created artificial compliance concerns and significant practical difficulties.
Read this article in Pharmaceutical Technology's Biologics and Sterile Drug Manufacturing eBook.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing
May 2020
Pages: 10–14, 43
Citation
When referring to this article, please cite it as J. Agalloco, "Complications in Process Simulation Execution," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
